Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - ATOSSA THERAPEUTICS, INC. | v432918_10k.htm |
| EX-32.1 - EXHIBIT 32.1 - ATOSSA THERAPEUTICS, INC. | v432918_ex32-1.htm |
| EX-32.2 - EXHIBIT 32.2 - ATOSSA THERAPEUTICS, INC. | v432918_ex32-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ATOSSA THERAPEUTICS, INC. | v432918_ex31-1.htm |
| EX-31.2 - EXHIBIT 31.2 - ATOSSA THERAPEUTICS, INC. | v432918_ex31-2.htm |
| EX-22.1 - EXHIBIT 22.1 - ATOSSA THERAPEUTICS, INC. | v432918_ex22-1.htm |
| EX-10.35 - EXHIBIT 10.35 - ATOSSA THERAPEUTICS, INC. | v432918_ex10-35.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Atossa Genetics Inc.
Seattle, Washington
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-205308 and 333-208236 ), Form S-3 (No. 333-186248 and 333-192390), and Form S-8 (No. 333-185625 and 333-193952) of Atossa Genetics Inc. of our report dated March 30, 2016, relating to the consolidated financial statements, which appear in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Seattle, Washington
March 30, 2016